MeiraGTx Holdings PLC (MGTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MeiraGTx Holdings PLC (MGTX) has a cash flow conversion efficiency ratio of -8.050x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($46.63 Million) by net assets ($-5.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MeiraGTx Holdings PLC (MGTX) defensive interval to measure how many days the company can operate on defensive assets alone.
MeiraGTx Holdings PLC - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how MeiraGTx Holdings PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
MeiraGTx Holdings PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MeiraGTx Holdings PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Xinpeng Industry Co Ltd
SHE:002328
|
0.059x |
|
Mishra Dhatu Nigam Limited
NSE:MIDHANI
|
0.007x |
|
BlackRock Health Sciences Trust II
NYSE:BMEZ
|
0.103x |
|
Vaudoise Assurances Holding SA
SW:VAHN
|
-0.006x |
|
Xian Peri Power Semiconductor Cond
SHE:300831
|
0.024x |
|
Oppenheimer Holdings Inc
NYSE:OPY
|
0.069x |
|
Changchun Zhiyuan New Energy Equipment Co. Ltd
SHE:300985
|
0.128x |
|
China Petrochemical Development Corp
TW:1314
|
0.009x |
Annual Cash Flow Conversion Efficiency for MeiraGTx Holdings PLC (2016–2025)
The table below shows the annual cash flow conversion efficiency of MeiraGTx Holdings PLC from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see MGTX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-5.79 Million | $-46.36 Million | 8.003x | +619.44% |
| 2024-12-31 | $67.83 Million | $-104.50 Million | -1.541x | -102.04% |
| 2023-12-31 | $138.18 Million | $-105.36 Million | -0.763x | -22.82% |
| 2022-12-31 | $117.74 Million | $-73.10 Million | -0.621x | -993.13% |
| 2021-12-31 | $185.40 Million | $-10.53 Million | -0.057x | +78.82% |
| 2020-12-31 | $238.56 Million | $-63.97 Million | -0.268x | -355.23% |
| 2019-12-31 | $190.80 Million | $20.04 Million | 0.105x | +114.46% |
| 2018-12-31 | $81.06 Million | $-58.89 Million | -0.726x | -290.58% |
| 2017-12-31 | $-47.37 Million | $-18.06 Million | 0.381x | -54.53% |
| 2016-12-31 | $-17.14 Million | $-14.37 Million | 0.838x | -- |
About MeiraGTx Holdings PLC
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xe… Read more